Nordic Nanovector ASA announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody coupled with the alpha-particle-generator lead-212, at the Society of Nuclear Medicine & Molecular Imaging 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June.
OSLO, Norway, June 11, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® (177Lu-lilotomab satetraxetan) and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) coupled with the alpha-particle-generator lead-212 (212Pb), at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June.
Details of the presentations are:
Combination of 177Lu-lilotomab satetraxetan with rituximab synergistically improves in-vivo therapeutic efficacy in a rituximab-resistant non-Hodgkin lymphoma (NHL) model
- Authors: M.M. Malenge, A.H. Ree, T. Stokke, J. Dahle and A.H.V. Repetto-Llamazares
- Abstract: 351 (click to access abstract online)
- Session: 42. Oncology, Basic and Translational (Basic Science) III
- Date/time: 24 June, 17:25-17:35 Pacific daylight time (PDT)
Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
- Authors: A. Saidi, A.F. Maaland, J. Torgue, H. Heyerdahl and J. Dahle
- Abstract: 354 (click to access abstract online)
- Session: 42. Oncology, Basic and Translational (Basic Science) III
- Date/time: 24 June, 17:55-18:05 PDT
The posters will be added to www.nordicnanovector.com in the section What We Do/Scientific Publications/Scientific Posters on 24 June to coincide with the sessions in which they are presented.
For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-presentations-at-the-society-of-nuclear-medicine--molecular-imaging-snmmi-2019-annual-meeting-300865167.html
SOURCE Nordic Nanovector
Company Codes: Bloomberg:NANO@NO, Dusseldorf:8NN, ISIN:NO0010597883, LSE:0R6Y, Oslo:NANO, RICS:NANO.OL, Stockholm:NANOO, Frankfurt:8NN, Stuttgart:8NN
